Medicinal Research Reviews最新文献_第9页

FDA-Approved Pyrimidine-Containing Drugs: Synthesis and Clinical Application fda批准的含嘧啶药物：合成和临床应用。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2026-04-08 Epub Date: 2025-11-20 DOI: 10.1002/med.70027

Yao Zhang, Xiaomei Liu, Chong Zhang, Yanke Li, Guangzhe Zhang, Zhenhua Du

引用次数: 0

The Potential, Challenges and New Horizons of Marine Natural Products Against Tuberculosis Infection 海洋天然产物抗结核感染的潜力、挑战和新前景。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2026-04-08 Epub Date: 2025-12-07 DOI: 10.1002/med.70028

Qun Zhang, Yi-Qian Han, Wei-Feng Xu, Mei-Yan Wei, Yu-Cheng Gu, Chang-Lun Shao

{"title":"The Potential, Challenges and New Horizons of Marine Natural Products Against Tuberculosis Infection","authors":"Qun Zhang, Yi-Qian Han, Wei-Feng Xu, Mei-Yan Wei, Yu-Cheng Gu, Chang-Lun Shao","doi":"10.1002/med.70028","DOIUrl":"10.1002/med.70028","url":null,"abstract":"<div>\u0000 \u0000 <p>Tuberculosis (TB) is one of the most significant health perils that has claimed more lives than any other contagious disease over the past 2000 years. The treatment of tuberculosis has been severely compromised due to drug-resistant strains. In this review, we cover the field of the clinical pipeline of tuberculosis drugs, and summarize the progress of their targets and structures. A wide range of marine natural products (MNPs) with novel structures and remarkable activities have potential for the development of antituberculosis drugs. We systematically summarize the progress and potential of 107 potent MNPs that have shown activity against tuberculosis infection. Additionally, we highlight the physicochemical properties of MNPs, total synthesis, and biosynthesis of bioactive compounds, to further evaluate their drug-likeness and sustainability of compound supply. However, the intricate nature of the pathogen, drug misuse, bottlenecks in the supply of MNPs, and other problems pose challenges to reaching the goal of completely eradicating tuberculosis worldwide. Reliable alternative models, screening based on enzyme activity, and combination therapies may be transforming discovery and application in the field of antituberculosis drugs, accelerating discovery and improving sustainable therapeutic effects. These promising lead compounds and widely emerging technologies broaden horizons for developing marine drugs.</p></div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 3","pages":"774-802"},"PeriodicalIF":11.6,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The IL-23/IL-17/NF-κB Signaling Pathway in Rheumatoid Arthritis: Molecular Mechanisms and Therapeutic Agents 类风湿关节炎中的IL-23/IL-17/NF-κB信号通路：分子机制和治疗药物。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2026-04-08 Epub Date: 2025-11-16 DOI: 10.1002/med.70024

Jiayi Deng, Yasi Deng, Yuxin Chen, Fan Bai, Bowen Zhang, Wuyang Jiang, Wei Wang, Huanghe Yu

{"title":"The IL-23/IL-17/NF-κB Signaling Pathway in Rheumatoid Arthritis: Molecular Mechanisms and Therapeutic Agents","authors":"Jiayi Deng, Yasi Deng, Yuxin Chen, Fan Bai, Bowen Zhang, Wuyang Jiang, Wei Wang, Huanghe Yu","doi":"10.1002/med.70024","DOIUrl":"10.1002/med.70024","url":null,"abstract":"<div>\u0000 \u0000 <p>Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joint synovium, which can lead to bone destruction. Prolonged inadequate treatment can result in joint disability and an increased risk of mortality. Currently, there are considerable limitations in the availability of effective therapeutic agents for RA. The IL-23/IL-17/NF-κB signaling pathway has emerged as a central pathogenic mechanism underlying the multistage development of RA. This pathway initiates the initial inflammatory response, driving excessive proliferation of the synovial tissue, ultimately leading to late-stage bone and cartilage destruction. A comprehensive understanding of the role of the IL-23/IL-17/NF-κB pathway in the pathogenesis of RA can facilitate the refinement of scientific understanding of RA pathogenesis and assist in developing new therapeutic regimens. A comprehensive literature review and data search were conducted in several scientific databases, including Web of Science, PubMed, Google Scholar, Embase, TCMSP, PubChem, Swiss ADME, and Swiss Target Prediction. The literature review was conducted from 2013 to 2025. The search terms employed included RA, IL-23, IL-17, NF-κB, molecular mechanisms, and therapeutic agents. Following a rigorous screening process, irrelevant data were excluded, resulting in a focused analysis and comprehensive review of the key role of the IL-23/IL-17/NF-κB signaling axis in the multifaceted pathogenesis of RA and the key active ingredients and possible targets of action of related drugs. This comprehensive literature review aims to provide novel mechanistic insights and valuable references to guide the development of more effective therapeutic strategies for this debilitating autoimmune disease.</p>\u0000 </div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 3","pages":"625-671"},"PeriodicalIF":11.6,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145533944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kinin B1 and B2 Receptors: Role in Tumor Progression and Pain Associated With Tumor and Anticancer Therapy 激肽B1和B2受体：与肿瘤和抗癌治疗相关的肿瘤进展和疼痛的作用。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2026-04-08 Epub Date: 2025-11-11 DOI: 10.1002/med.70019

Indiara Brusco, Sara Marchesan Oliveira

{"title":"Kinin B1 and B2 Receptors: Role in Tumor Progression and Pain Associated With Tumor and Anticancer Therapy","authors":"Indiara Brusco, Sara Marchesan Oliveira","doi":"10.1002/med.70019","DOIUrl":"10.1002/med.70019","url":null,"abstract":"<div>\u0000 \u0000 <p>Cancer is the second leading cause of death globally, with an estimated worldwide incidence of 19.3 million cases in 2020, and is expected to increase by 47% in the next 20 years. Painful symptoms of tumors and anticancer treatment negatively impact the quality of life of patients with cancer. Cancer pain can occur during all disease periods, being more debilitating and hardest to treat, mainly when tumors metastasize to the bone. Common tumors such as breast, lung, and prostate often metastasize to the bones and cause severe pain in patients. Anticancer therapy with some chemotherapy and hormonal drugs also induces painful symptoms, compromising antineoplastic treatment. Among the analgesics recommended to treat cancer pain, NSAIDs and paracetamol seem to have predominantly antiproliferative activity. However, opioids, mainly morphine, present conflicting effects in reducing and promoting tumor progression. Kinins and their B<sub>1</sub> and B<sub>2</sub> receptors contribute to the development of numerous painful symptoms,including those induced by tumors and anticancer therapy. In addition, kinins stimulate the proliferation of various tumors (breast, lung, prostate and others) while having controversial effects in melanoma. Thus, kinin B<sub>1</sub> and B<sub>2</sub> receptors could be a promising pharmacological target to treat the pain caused by the tumor and its therapy while reducing tumor proliferation. However, it is essential to review the effects of kinins in each specific type of cancer to investigate their involvement in pain. This assessment is also valid and prudent for new analgesic candidates against cancer pain and their therapy, especially to rule out a possible pro-tumor activity of this analgesic.</p>\u0000 </div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 3","pages":"585-624"},"PeriodicalIF":11.6,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medicinal Chemistry Strategies for the Development of CD73 Inhibitors in Cancer Immunotherapy 肿瘤免疫治疗中CD73抑制剂开发的药物化学策略

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2026-04-08 Epub Date: 2025-12-04 DOI: 10.1002/med.70029

Meng Cui, Shaowei Ma, Zhe Huang, Danye Zhang, Xiaofei Sun, Yue You

{"title":"Medicinal Chemistry Strategies for the Development of CD73 Inhibitors in Cancer Immunotherapy","authors":"Meng Cui, Shaowei Ma, Zhe Huang, Danye Zhang, Xiaofei Sun, Yue You","doi":"10.1002/med.70029","DOIUrl":"10.1002/med.70029","url":null,"abstract":"<div>\u0000 \u0000 <p>CD73, a membrane-bound ecto-5′-nucleotidase, catalyzes the extracellular conversion of adenosine monophosphate into immunosuppressive adenosine. Functioning as an emerging immune checkpoint, CD73 is frequently upregulated across numerous tumor types, contributing to the accumulation of adenosine within the tumor microenvironment and promoting immune evasion. Intensive efforts have led to the discovery of diverse CD73 inhibitors, which show strong potential in cancer immunotherapy. To date, around eighteen candidates targeting CD73 have entered clinical evaluation, many exhibiting encouraging efficacy in combination regimens for solid tumors. This review provides an overview of the biological functions of CD73 in tumor-induced immunosuppression and highlights the medicinal chemistry strategies employed in the development of small-molecule CD73 inhibitors since 2018. Additionally, the challenges in drug design and future directions are also discussed to enhance the clinical applicability of CD73-targeted therapies in cancer treatment. We believe that this review will offer valuable insights to guide the rational design of next-generation CD73 inhibitors for cancer immunotherapy.</p></div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 3","pages":"749-773"},"PeriodicalIF":11.6,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development 苯二氮卓类变构调节剂的进化：从药物发现和开发的历史里程碑到新兴创新的结构见解。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2026-04-08 Epub Date: 2025-11-09 DOI: 10.1002/med.70026

Hongyu Jiang, Zhipeng Hu, Lixin Yang, Shengcong Chen, Dongbo Tang, Wei Shi, Hai Qian

{"title":"The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development","authors":"Hongyu Jiang, Zhipeng Hu, Lixin Yang, Shengcong Chen, Dongbo Tang, Wei Shi, Hai Qian","doi":"10.1002/med.70026","DOIUrl":"10.1002/med.70026","url":null,"abstract":"<div>\u0000 \u0000 <p>Benzodiazepine drugs (BZDs) have been central to neuropsychopharmacology since the 1960s, acting as positive allosteric modulators of γ-aminobutyric acid type A (GABA<sub>A</sub>) receptors to enhance inhibitory neurotransmission. Despite their clinical efficacy, long-term use is limited by tolerance, dependence, and cognitive side effects. This review summarizes the structural evolution of BZD modulators, with a focus on subtype-selective interactions with GABA<sub>A</sub> receptor isoforms. Advances in cryo-electron microscopy and AI-driven modeling have clarified the architecture and pharmacological roles of distinct receptor subunits, enabling the design of ligands that dissociate therapeutic effects from adverse outcomes. We also highlight the development of nonclassical scaffolds—such as imidazopyridines, triazolopyridazines, and cinnolines—which improve metabolic stability and subtype specificity. In addition, emerging formulation technologies and novel indications, including chronic pain, asthma, and neurodegenerative disorders, broaden the therapeutic scope of BZD-related compounds. Collectively, these advances underscore a shift toward rational, structure-based design of next-generation BZD receptor modulators with improved efficacy, safety, and clinical precision.</p></div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 3","pages":"561-584"},"PeriodicalIF":11.6,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Front Cover Image, Volume 46, Issue 1 封面图像，第46卷，第1期

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2025-12-03 DOI: 10.1002/med.70031

Yuting Xin, Fangsu Chen, Qidong You, Lei Wang, Qiuyue Zhang

引用次数: 0

Design and Development of Small-Molecule Drugs Targeting Enzymes Utilizing Two-Metal-Ion Catalytic Mechanisms 利用双金属离子催化机制设计和开发靶向酶的小分子药物。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2025-10-30 DOI: 10.1002/med.70023

Chenzhong Liao, Xuezhi Zhao, Qin Wang

{"title":"Design and Development of Small-Molecule Drugs Targeting Enzymes Utilizing Two-Metal-Ion Catalytic Mechanisms","authors":"Chenzhong Liao, Xuezhi Zhao, Qin Wang","doi":"10.1002/med.70023","DOIUrl":"10.1002/med.70023","url":null,"abstract":"<div>\u0000 \u0000 <p>The active sites of numerous metalloproteins feature two metal ion cofactors—either identical or distinct—that are positioned in close proximity, typically around 3.8 Å apart. This two-metal-ion catalytic mechanism (TCM) endows these enzymes with a remarkable catalytic efficiency. Enzymes employing TCM play vital biological roles in both humans and pathogenic organisms, with some identified as validated therapeutic targets. Various rational drug design approaches, including nucleoside analogs, prodrugs, metal-binding group design, bioisosteres, pharmacophore modeling, scaffold hopping, tautomerism, and structure-based drug design, have been successfully applied to several enzymes with TCMs, thus yielding the development and approval of many small-molecule drugs for the treatment of several diseases, including certain catastrophic illnesses, such as hepatitis C infection, coronavirus disease 2019, and acquired immune deficiency syndrome. Additionally, drug repurposing has proven to be a critical strategy in the development of therapeutics targeting TCM enzymes. This article reviews the significant achievements in design and development of small-molecule drugs targeting several enzymes with TCMs, including RNA-dependent RNA polymerase, HIV-1 integrase, influenza virus cap-dependent endonuclease, and phosphodiesterase, hoping to offer valuable insights and guidance to facilitate future drug discovery efforts focused on these enzymes and related molecular targets.</p>\u0000 </div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 2","pages":"542-556"},"PeriodicalIF":11.6,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological Potential of Jellyfish Bioactive Peptides: From Neurodegenerative Disorders to Cancers 水母生物活性肽的药理潜力：从神经退行性疾病到癌症。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2025-10-30 DOI: 10.1002/med.70022

Yining Lei, Jiaming Zhang, Gaochi Xu, Aili Wang, Zhijian Cao

{"title":"Pharmacological Potential of Jellyfish Bioactive Peptides: From Neurodegenerative Disorders to Cancers","authors":"Yining Lei, Jiaming Zhang, Gaochi Xu, Aili Wang, Zhijian Cao","doi":"10.1002/med.70022","DOIUrl":"10.1002/med.70022","url":null,"abstract":"<div>\u0000 \u0000 <p>Jellyfish are vital components of marine ecosystems and significantly impact human life and industry. Globally, jellyfish populations are increasing annually, but their applications are currently limited primarily to food processing. Jellyfish contain various peptides and proteins that humans can utilize because of their unique biological structures and compositions. In particular, jellyfish are rich in bioactive peptides that intrigue researchers. Jellyfish bioactive peptides can be categorized functionally into toxin peptides, neuropeptides, antioxidant peptides, angiotensin-converting enzyme (ACE) inhibitory peptides, and antimicrobial peptides (AMPs), each with distinct physiological roles, such as inflammation, apoptosis, ion pathway, reproduction, and vision. They are demonstrated to have valuable pharmacological potential against various diseases, including neurodegenerative disorders, wound healing, osteoarthritis and cancer, and are candidate for nutraceuticals. This review primarily summarizes the reported bioactive peptides from jellyfish, improving our understanding of their potential pharmacological effects and nutraceutical activities, which may promote the further utilization and development of bioactive peptides from jellyfish.</p>\u0000 </div>","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"46 2","pages":"513-541"},"PeriodicalIF":11.6,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human Cyclophilins—An Emerging Class of Drug Targets 人类亲环蛋白——一类新兴的药物靶点。

IF 11.6 1区医学

Medicinal Research Reviews Pub Date : 2025-10-29 DOI: 10.1002/med.70021

Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek

引用次数: 0